Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15964345rdf:typepubmed:Citationlld:pubmed
pubmed-article:15964345lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:15964345lifeskim:mentionsumls-concept:C0376387lld:lifeskim
pubmed-article:15964345lifeskim:mentionsumls-concept:C0022671lld:lifeskim
pubmed-article:15964345pubmed:issue5lld:pubmed
pubmed-article:15964345pubmed:dateCreated2005-6-20lld:pubmed
pubmed-article:15964345pubmed:abstractTextFrom 1992 to 2001 hepatitis C virus (HCV) viremia was studied in 53 renal transplant recipients anti-HCV+ with at least 3 months follow-up posttransplant using a quantitative retrotranscriptase-PCR method. HCV-RNA was detected in 45 (85%): 29 of the 34 recipients treated with azathioprine-based therapy and 15 of 18 treated with mycophenolate mofetil. Immunosuppressive therapy type did not affect HCV replication. Three different patterns of HCV-RNA evolution were detected: 13 (28.8%) patients with high RNA-HCV levels; 21 (46.7%) patients with low levels; and 11 (24.4%) patients with viremia elevation. In 10 (90%) of 11 of the last group, HCV viremia was detected before 15 days posttransplantation, significantly earlier than in the other two groups. Thus, replication during the first 15 days after transplantation leads to a high RNA-HCV viral load. No clinical symptoms were related to HCV.lld:pubmed
pubmed-article:15964345pubmed:languageenglld:pubmed
pubmed-article:15964345pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15964345pubmed:citationSubsetIMlld:pubmed
pubmed-article:15964345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15964345pubmed:statusMEDLINElld:pubmed
pubmed-article:15964345pubmed:monthJunlld:pubmed
pubmed-article:15964345pubmed:issn0041-1345lld:pubmed
pubmed-article:15964345pubmed:authorpubmed-author:GomezEElld:pubmed
pubmed-article:15964345pubmed:authorpubmed-author:VillarMMlld:pubmed
pubmed-article:15964345pubmed:authorpubmed-author:de OñaMMlld:pubmed
pubmed-article:15964345pubmed:authorpubmed-author:CHIUS JSJlld:pubmed
pubmed-article:15964345pubmed:authorpubmed-author:GalarragaM...lld:pubmed
pubmed-article:15964345pubmed:authorpubmed-author:MelonSSlld:pubmed
pubmed-article:15964345pubmed:authorpubmed-author:LauresAAlld:pubmed
pubmed-article:15964345pubmed:issnTypePrintlld:pubmed
pubmed-article:15964345pubmed:volume37lld:pubmed
pubmed-article:15964345pubmed:ownerNLMlld:pubmed
pubmed-article:15964345pubmed:authorsCompleteYlld:pubmed
pubmed-article:15964345pubmed:pagination2083-5lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:meshHeadingpubmed-meshheading:15964345...lld:pubmed
pubmed-article:15964345pubmed:year2005lld:pubmed
pubmed-article:15964345pubmed:articleTitleHepatitis C virus reactivation in anti-hepatitic C virus-positive renal transplant recipients.lld:pubmed
pubmed-article:15964345pubmed:affiliationDepartment of Virology-Microbiology, Hospital Universitaria Central de Asturias, Celestino Villamil, s/n, Oviedo, Asturias 33006, Spain. santiago.melon@sespa.princast.eslld:pubmed
pubmed-article:15964345pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15964345lld:pubmed